patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_480084 | REC_0014201 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 6 | 60 | female | 0 | 19 | 5.4 | 2 | sotorasib 960 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:00.684381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766546 | REC_0014202 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.8 | 81 | female | 2 | 18 | 5.5 | 2 | alectinib 600 mg BID | 15.5 | false | MSS | 2026-03-15T05:36:00.684736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673668 | REC_0014203 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.8 | 57 | male | 1 | 21 | 4.5 | 1 | alectinib 600 mg BID | 26.3 | false | MSI-H | 2026-03-15T05:36:00.685088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503215 | REC_0014204 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12.7 | 76 | male | 1 | 8 | 5.2 | 4 | osimertinib 80 mg daily | 5.8 | true | MSI-H | 2026-03-15T05:36:00.685437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183446 | REC_0014205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16 | 72 | female | 2 | 13 | 4.7 | 6 | entrectinib 600 mg daily | 8.9 | false | MSS | 2026-03-15T05:36:00.685774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831680 | REC_0014206 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 17.3 | 56 | female | 0 | 15 | 8.8 | 1 | sotorasib 960 mg daily | 20 | false | MSI-H | 2026-03-15T05:36:00.686111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407081 | REC_0014207 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 13.3 | 71 | male | 2 | 17 | 4.2 | 2 | osimertinib 80 mg daily | 18.5 | true | MSS | 2026-03-15T05:36:00.686439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445641 | REC_0014208 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 7.8 | 54 | female | 0 | 13 | 6.6 | 5 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:36:00.686764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362212 | REC_0014209 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 14.1 | 77 | female | 2 | 17 | 5.3 | 6 | osimertinib 80 mg daily | 19 | false | MSI-H | 2026-03-15T05:36:00.687066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249467 | REC_0014210 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 9 | 69 | female | 0 | 26 | 4.5 | 0 | pembrolizumab 200 mg q3w | 21.1 | true | MSS | 2026-03-15T05:36:00.687558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745646 | REC_0014211 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 10.5 | 68 | female | 1 | 15 | 5.3 | 6 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.687929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761988 | REC_0014212 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 59 | female | 1 | 36 | 6 | 7 | pembrolizumab 200 mg q3w | 14.9 | true | MSS | 2026-03-15T05:36:00.688359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994490 | REC_0014213 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.5 | 57 | female | 0 | 36 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:36:00.688748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408591 | REC_0014214 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.6 | 60 | male | 1 | 16 | 3.7 | 8 | alectinib 600 mg BID | 8.7 | false | MSS | 2026-03-15T05:36:00.689109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756645 | REC_0014215 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 14.1 | 65 | female | 0 | 9 | 3.3 | 4 | osimertinib 80 mg daily | 6.2 | true | MSS | 2026-03-15T05:36:00.689481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446120 | REC_0014216 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 19.2 | 67 | female | 1 | 10 | 6.7 | 4 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:36:00.689825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986295 | REC_0014217 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.5 | 63 | male | 0 | 14 | 4 | 5 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:36:00.690175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198366 | REC_0014218 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.7 | 71 | female | 1 | 7 | 7.3 | 2 | alectinib 600 mg BID | 22.6 | false | MSS | 2026-03-15T05:36:00.690494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354777 | REC_0014219 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 18.9 | 78 | female | 2 | 10 | 3.4 | 2 | entrectinib 600 mg daily | 29.5 | false | MSI-H | 2026-03-15T05:36:00.690818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527570 | REC_0014220 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 21 | 11.3 | 69 | female | 0 | 21 | 4.5 | 0 | alectinib 600 mg BID | 45.1 | false | MSS | 2026-03-15T05:36:00.691154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981601 | REC_0014221 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.8 | 72 | female | 2 | 16 | 7.5 | 3 | pembrolizumab 200 mg q3w | 4.4 | true | MSS | 2026-03-15T05:36:00.691507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621484 | REC_0014222 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 11 | 72 | female | 1 | 15 | 7.3 | 4 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:36:00.691851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756180 | REC_0014223 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5 | 54 | male | 0 | 38 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:36:00.692464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330792 | REC_0014224 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 14.6 | 64 | female | 0 | 21 | 5.2 | 6 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:36:00.692882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924325 | REC_0014225 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 11.3 | 52 | male | 0 | 20 | 6.9 | 8 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:36:00.693251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146594 | REC_0014226 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 1.5 | 71 | female | 2 | 19 | 4.7 | 0 | osimertinib 80 mg daily | 63.5 | true | MSS | 2026-03-15T05:36:00.693576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937262 | REC_0014227 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.8 | 74 | female | 2 | 51 | 5.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:36:00.693922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461755 | REC_0014228 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 14.6 | 69 | female | 0 | 17 | 5.6 | 7 | pembrolizumab 200 mg q3w | 12 | true | MSI-H | 2026-03-15T05:36:00.694277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235933 | REC_0014229 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 22.3 | 51 | male | 0 | 14 | 6.2 | 4 | sotorasib 960 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:00.694617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941738 | REC_0014230 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 12.8 | 90 | female | 1 | 15 | 4.5 | 1 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:00.694973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698266 | REC_0014231 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12 | 56 | female | 1 | 10 | 3.7 | 8 | entrectinib 600 mg daily | 8.1 | false | MSS | 2026-03-15T05:36:00.695310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535903 | REC_0014232 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.3 | 67 | male | 0 | 35 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:36:00.695646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444448 | REC_0014233 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.6 | 58 | male | 0 | 52 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:36:00.695997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969123 | REC_0014234 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.2 | 75 | female | 3 | 54 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:36:00.696477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821612 | REC_0014235 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.9 | 56 | female | 0 | 7 | 5.4 | 9 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:36:00.696882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717530 | REC_0014236 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.3 | 76 | female | 2 | 54 | 5.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.4 | true | MSS | 2026-03-15T05:36:00.697406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866504 | REC_0014237 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.7 | 71 | female | 2 | 9 | 6.4 | 5 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:00.697796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463284 | REC_0014238 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 8.4 | 79 | male | 2 | 13 | 5 | 5 | entrectinib 600 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:00.698141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136800 | REC_0014239 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 8.7 | 65 | female | 1 | 21 | 4 | 1 | osimertinib 80 mg daily | 29.5 | true | MSS | 2026-03-15T05:36:00.698481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603479 | REC_0014240 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 13.6 | 65 | male | 0 | 18 | 7.3 | 7 | pembrolizumab 200 mg q3w | 13 | true | MSI-H | 2026-03-15T05:36:00.698835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992542 | REC_0014241 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 16 | 10.4 | 53 | female | 0 | 16 | 6.6 | 1 | pembrolizumab 200 mg q3w | 15.2 | false | MSI-H | 2026-03-15T05:36:00.699180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333636 | REC_0014242 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 12.4 | 67 | female | 1 | 25 | 7.1 | 4 | entrectinib 600 mg daily | 17.3 | true | MSS | 2026-03-15T05:36:00.699518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302857 | REC_0014243 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 37 | 14.8 | 65 | female | 1 | 23 | 9.3 | 5 | osimertinib 80 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:36:00.699853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711205 | REC_0014244 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 13 | 79 | female | 2 | 0 | 4.1 | 0 | entrectinib 600 mg daily | 31 | true | MSS | 2026-03-15T05:36:00.700257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306409 | REC_0014245 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 13.6 | 63 | male | 1 | 25 | 6.9 | 1 | sotorasib 960 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:36:00.700621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723466 | REC_0014246 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.4 | 68 | female | 0 | 19 | 5.6 | 1 | pembrolizumab 200 mg q3w | 18.6 | true | MSS | 2026-03-15T05:36:00.700974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150393 | REC_0014247 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 14.7 | 54 | female | 0 | 20 | 3.7 | 1 | pembrolizumab 200 mg q3w | 14.6 | true | MSI-H | 2026-03-15T05:36:00.701333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344885 | REC_0014248 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.4 | 67 | female | 1 | 10 | 6.5 | 6 | osimertinib 80 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:36:00.701694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885037 | REC_0014249 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 19.3 | 66 | female | 1 | 16 | 6.1 | 1 | osimertinib 80 mg daily | 15.8 | false | MSI-H | 2026-03-15T05:36:00.702179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359582 | REC_0014250 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 18.5 | 59 | female | 1 | 11 | 7.3 | 4 | osimertinib 80 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:36:00.702541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908017 | REC_0014251 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 8.6 | 74 | female | 1 | 68 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:36:00.702872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414103 | REC_0014252 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12.4 | 77 | female | 1 | 11 | 6.6 | 1 | osimertinib 80 mg daily | 17.5 | true | MSI-H | 2026-03-15T05:36:00.703221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332050 | REC_0014253 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.2 | 73 | female | 2 | 7 | 7.5 | 2 | osimertinib 80 mg daily | 26.1 | true | MSS | 2026-03-15T05:36:00.703560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901909 | REC_0014254 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.3 | 71 | female | 2 | 35 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:36:00.703890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315176 | REC_0014255 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.6 | 79 | female | 1 | 10 | 4.3 | 7 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:00.704301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962071 | REC_0014256 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 17.8 | 70 | female | 1 | 17 | 5.6 | 1 | osimertinib 80 mg daily | 28.4 | true | MSS | 2026-03-15T05:36:00.704679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563330 | REC_0014257 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 8.7 | 70 | female | 0 | 11 | 6 | 1 | pembrolizumab 200 mg q3w | 32.4 | false | MSS | 2026-03-15T05:36:00.705011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339437 | REC_0014258 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 13.6 | 73 | female | 2 | 23 | 6.6 | 1 | osimertinib 80 mg daily | 29.2 | true | MSI-H | 2026-03-15T05:36:00.705341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409067 | REC_0014259 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 8.6 | 61 | male | 1 | 14 | 5.9 | 5 | osimertinib 80 mg daily | 5 | true | MSS | 2026-03-15T05:36:00.705680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234350 | REC_0014260 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.3 | 54 | male | 0 | 31 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.4 | true | MSS | 2026-03-15T05:36:00.706011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127397 | REC_0014261 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 17.6 | 64 | female | 0 | 13 | 7.1 | 7 | osimertinib 80 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:36:00.706366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174423 | REC_0014262 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 14.9 | 67 | female | 1 | 22 | 6.4 | 2 | entrectinib 600 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:36:00.706928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732337 | REC_0014263 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 15.1 | 60 | male | 0 | 15 | 6.3 | 5 | sotorasib 960 mg daily | 6.4 | false | MSS | 2026-03-15T05:36:00.707368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220436 | REC_0014264 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.9 | 59 | female | 1 | 10 | 5.2 | 4 | entrectinib 600 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:36:00.707775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338478 | REC_0014265 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 15 | 8.5 | 52 | female | 0 | 11 | 7.8 | 2 | pembrolizumab 200 mg q3w | 21.5 | false | MSS | 2026-03-15T05:36:00.708241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809585 | REC_0014266 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 6.5 | 81 | male | 1 | 16 | 5.6 | 5 | entrectinib 600 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:00.708681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823547 | REC_0014267 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 9.1 | 59 | male | 1 | 18 | 4.4 | 1 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:36:00.709088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808185 | REC_0014268 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 1.7 | 66 | female | 1 | 6 | 5.8 | 5 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:36:00.709449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273190 | REC_0014269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 12.5 | 66 | female | 1 | 8 | 6.2 | 3 | osimertinib 80 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:36:00.709828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709847 | REC_0014270 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 14.5 | 72 | male | 2 | 14 | 5.5 | 0 | osimertinib 80 mg daily | 31.9 | false | MSS | 2026-03-15T05:36:00.710162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317014 | REC_0014271 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6 | 62 | male | 1 | 17 | 3.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.5 | false | MSS | 2026-03-15T05:36:00.710517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725191 | REC_0014272 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 13.5 | 64 | female | 1 | 10 | 6.5 | 5 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:36:00.710891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509563 | REC_0014273 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 17.3 | 65 | female | 0 | 14 | 3.7 | 2 | alectinib 600 mg BID | 21.1 | true | MSS | 2026-03-15T05:36:00.711254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730646 | REC_0014274 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 9.8 | 69 | female | 0 | 18 | 4 | 7 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:36:00.711593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811285 | REC_0014275 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 9.1 | 64 | female | 1 | 21 | 8.3 | 1 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:36:00.712057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217231 | REC_0014276 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.7 | 60 | female | 1 | 12 | 5.7 | 2 | osimertinib 80 mg daily | 22.7 | true | MSS | 2026-03-15T05:36:00.712484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721372 | REC_0014277 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 13.6 | 65 | female | 0 | 21 | 6.3 | 2 | pembrolizumab 200 mg q3w | 18.2 | true | MSI-H | 2026-03-15T05:36:00.712831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554777 | REC_0014278 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 9.1 | 65 | female | 0 | 12 | 6.4 | 0 | entrectinib 600 mg daily | 41.1 | false | MSS | 2026-03-15T05:36:00.713174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773466 | REC_0014279 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.3 | 62 | male | 0 | 7 | 6.1 | 4 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:36:00.713553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974404 | REC_0014280 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.5 | 62 | male | 0 | 20 | 5.3 | 5 | entrectinib 600 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:36:00.713908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533945 | REC_0014281 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 19.1 | 57 | male | 1 | 20 | 7.6 | 5 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:00.714283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542013 | REC_0014282 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.6 | 73 | female | 2 | 15 | 6.5 | 9 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.714647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497822 | REC_0014283 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.8 | 49 | female | 0 | 10 | 5.8 | 6 | entrectinib 600 mg daily | 11.9 | true | MSI-H | 2026-03-15T05:36:00.717771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712161 | REC_0014284 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.8 | 72 | female | 2 | 16 | 8.2 | 6 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:36:00.718328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968361 | REC_0014285 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 8.8 | 60 | male | 1 | 16 | 5.6 | 5 | alectinib 600 mg BID | 6.2 | true | MSS | 2026-03-15T05:36:00.718672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317951 | REC_0014286 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8.7 | 59 | female | 0 | 50 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:36:00.719022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264429 | REC_0014287 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 15.3 | 76 | male | 1 | 7 | 6.4 | 1 | pembrolizumab 200 mg q3w | 17.8 | false | MSI-H | 2026-03-15T05:36:00.719341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231366 | REC_0014288 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 17.3 | 52 | male | 0 | 10 | 3.1 | 5 | alectinib 600 mg BID | 6.4 | false | MSI-H | 2026-03-15T05:36:00.719838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412745 | REC_0014289 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 10.2 | 70 | female | 1 | 10 | 7.7 | 2 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:00.720303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701571 | REC_0014290 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 10.3 | 72 | female | 1 | 14 | 6.5 | 0 | entrectinib 600 mg daily | 30.9 | true | MSS | 2026-03-15T05:36:00.720654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832520 | REC_0014291 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 6.1 | 66 | female | 0 | 15 | 7 | 8 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:36:00.721028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945462 | REC_0014292 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.3 | 68 | female | 1 | 57 | 8 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:36:00.721363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566314 | REC_0014293 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.8 | 71 | female | 1 | 72 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.2 | true | MSS | 2026-03-15T05:36:00.721701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757546 | REC_0014294 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.4 | 74 | male | 1 | 9 | 6 | 7 | osimertinib 80 mg daily | 5.4 | true | MSI-H | 2026-03-15T05:36:00.722077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862427 | REC_0014295 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.7 | 83 | female | 1 | 66 | 3.5 | 4 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:00.722469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290373 | REC_0014296 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.1 | 68 | female | 1 | 24 | 5.5 | 1 | alectinib 600 mg BID | 12.5 | false | MSS | 2026-03-15T05:36:00.722883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593235 | REC_0014297 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.8 | 78 | male | 1 | 58 | 6.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 24.9 | false | MSS | 2026-03-15T05:36:00.723282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256524 | REC_0014298 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.4 | 78 | female | 1 | 63 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 28.9 | false | MSS | 2026-03-15T05:36:00.723674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445297 | REC_0014299 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 1.5 | 67 | female | 1 | 12 | 5.3 | 8 | entrectinib 600 mg daily | 13.1 | false | MSS | 2026-03-15T05:36:00.724054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716036 | REC_0014300 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3 | 71 | female | 2 | 19 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:36:00.724496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.